Abstract
Introduction
This study focused on the evaluation of data concerning the clinical features of patients who were initially diagnosed with bone metastases of carcinoma from unknown primary sites that could not be detected, even using state of-the-art diagnostic modalities.
Method
The oncologic outcome of these patients is discussed.
Patients
The clinical records of seven patients who had presented with bone metastases of carcinoma from unknown primary sites were retrospectively reviewed. Clinical features, treatment and outcome were analyzed. Extraskeletal metastases were located in the lymph nodes, liver, skeletal muscle, kidney, adrenal gland, and pleura. Six cases were observed in the pelvis, three in the femur, three in the skull, two in the rib, two in the cervical spine, two in the thoracic spine, two in the lumbar spine, one in the humerus, one in the radius, one in the clavicle, one in the scapula and one in the sternum. Four patients received systemic chemotherapy including platinum.
Results
At the last follow-up time of average 272 days, six patients were dead of disease and one patient was alive with disease. Although considerable progress has been made in the development of diagnostic modalities, including more recently FDG-PET, the primary tumor site cannot always be identified. Multiple bone and visceral organ metastases are often present in patients whose primary tumor was not detected.
Conclusion
In the present study, it was found that systemic chemotherapy can appreciably increase the survival time of the patients with carcinoma metastases from unknown primary sites.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL (1999) Classification and regression tree analysis of 1,000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403–3410
Rougraff BT (2003) Evaluation of the patient with carcinoma of unknown origin metastatic to bone. Clin Orthop Relat Res 415:105–109
Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005
Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H (2000) Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study. Cancer 88:1759–1761
Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A (1989) Metastatic bone disease from occult carcinoma: a profile. Int Orthop 13:119–123
Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, Vaalburg W, Vermey A (1998) Detection of unknown occult primary tumors using positron emission tomography. Cancer 82:1160–1166
Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR (2007) The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109:292–299
Bécouarn Y, Brunet R, Barbé-Gaston C (1989) Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer Clin Oncol 25:861–865
Briasoulis E, Tsavaris N, Fountzilas G, Athanasiadis A, Kosmidis P, Bafaloukos D, Skarlos D, Samantas E, Pavlidis N (1998) Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: a Hellenic co-operative oncology group phase II study. Oncology 55:426–430
Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD (2000) Carcinoma of unknown primary site. Cancer 89:2655–2660
Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N (2000) Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic cooperative oncology group study. J Clin Oncol 18:3101–3107
Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20:1651–1656
Piga A, Nortilli R, Cetto GL, Cardarelli N, Fedeli SL, Fiorentini G, D’Aprile M, Giorgi F, Parziale AP, Contu A, Montironi R, Gesuita R, Carle F, Cellerino R (2004) Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. Br J Cancer 90:1898–1904
Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S, Yeend SJ, Price TJ, Adelaide Cancer Trials and Education Collaborative (ACTEC) (2006) Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer 95:1309–1313
Nakanishi K, Kobayashi M, Takahashi S, Nakata S, Kyakuno M, Nakaguchi K, Nakamura H (2005) Whole body MRI for detecting metastatic bone tumor: comparison with bone scintigrams. Magn Reson Med Sci 4:11–17
Yam LT, Winkler CF, Janckila AJ, Li CY, Lam KW (1983) Prostatic cancer presenting as metastatic adenocarcinoma of undetermined origin. Immunodiagnosis by prostatic acid phosphatase. Cancer 51:283–287
Battifora H (1984) Recent progress in the immunohistochemistry of solid tumors. Semin Diagn Pathol 1:251–271
Herrera GA, Reimann BE (1984) Electron microscopy in determining origin of metastatic adenocarcinomas. South Med J 77:1557–1566
Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD (2008) Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:44424–44448
Conflict of interest statement
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hoshi, M., Taguchi, S., Hayakawa, K. et al. Evaluation of clinical problems associated with bone metastases from carcinoma from unknown primary sites. Arch Orthop Trauma Surg 131, 59–64 (2011). https://doi.org/10.1007/s00402-010-1102-7
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-010-1102-7